News articles about bluebird bio (NASDAQ:BLUE) have trended somewhat positive recently, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. bluebird bio earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 44.950889663772 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Global Thalassemia Market Size, Status and Forecast 2025 : Bluebird bio, Inc., Gamida Cell, Kiadis Pharma (openpr.com)
- 4 Biotechs Ready for Big Rebounds (finance.yahoo.com)
- bluebird bio Inc (BLUE) Insider David Davidson Sells 22,000 Shares (americanbankingnews.com)
- bluebird bio (BLUE) PT Raised to $162.00 (americanbankingnews.com)
- bluebird bio (BLUE) Lowered to “Sell” at BidaskClub (americanbankingnews.com)
A number of analysts have commented on BLUE shares. Cantor Fitzgerald reiterated a “sell” rating and set a $113.00 target price (down from $122.00) on shares of bluebird bio in a research report on Wednesday, February 21st. Barclays reiterated an “overweight” rating and set a $209.00 target price (up from $162.00) on shares of bluebird bio in a research report on Wednesday, December 13th. Zacks Investment Research downgraded bluebird bio from a “hold” rating to a “sell” rating in a research report on Monday, February 26th. William Blair reiterated a “buy” rating on shares of bluebird bio in a research report on Friday, March 16th. Finally, Jefferies Group upgraded bluebird bio from a “hold” rating to a “buy” rating and boosted their target price for the stock from $130.00 to $211.00 in a research report on Monday, December 11th. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $195.20.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported ($2.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.84). bluebird bio had a negative return on equity of 28.09% and a negative net margin of 947.42%. The company had revenue of $4.17 million during the quarter, compared to analyst estimates of $7.11 million. During the same period last year, the firm earned ($1.88) earnings per share. The business’s revenue was up 169.0% compared to the same quarter last year. analysts forecast that bluebird bio will post -8.39 EPS for the current fiscal year.
In other news, insider Jason Cole sold 25,000 shares of the business’s stock in a transaction on Tuesday, January 30th. The stock was sold at an average price of $195.91, for a total value of $4,897,750.00. Following the completion of the transaction, the insider now directly owns 44,798 shares of the company’s stock, valued at $8,776,376.18. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider David Davidson sold 22,000 shares of the business’s stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $167.52, for a total value of $3,685,440.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 80,034 shares of company stock valued at $15,122,163. Insiders own 3.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3336542/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-bluebird-bio-blue-share-price.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.